Assessing disability progression using the WHODAS 2.0 in multiple sclerosis: Investigating clinical and socio-demographic factors in a large longitudinal cohort study (TONiC-MS)
The interplay between self-efficacy, education and disability reinforces the importance of interventions seeking to enhance self-efficacy. Our results additionally support early monitoring and targeting of comorbidities and smoking, which could reduce disability progression. The associations of time-varying depression and fatigue with disability also offer important opportunities for treatment. Characterising disability progression via validated measures provides information, targets for health promotion and indicators of groups warranting closer monitoring.
Authors
- Alan Tennant (ORCID: https://orcid.org/0000-0002-0728-2130)
- Kate M. Tilling (ORCID: https://orcid.org/0000-0002-1010-8926)
- Yoav Ben‐Shlomo (ORCID: https://orcid.org/0000-0001-6648-3007)
- Cris S. Constantinescu (ORCID: https://orcid.org/0000-0003-2066-7585)
- Carolyn Young (ORCID: https://orcid.org/0000-0003-1745-7720)
- Seema Kalra (ORCID: https://orcid.org/0000-0001-5405-2445)
- Randall M. Parker (ORCID: https://orcid.org/0000-0002-3933-9728)
- Roger Mills
Institutions
- University of Liverpool (GB)
- University Hospitals of North Midlands NHS Trust (GB)
- Walton Centre (GB)
- University of Bristol (GB)
- Cooper Medical School of Rowan University (US)
- NIHR Leeds Musculoskeletal Biomedical Research Unit (GB)
- Merseytravel (GB)
Publication Details
- Journal
- Multiple Sclerosis and Related Disorders
- Published
- 2024-12-10
- DOI
- https://doi.org/10.1016/j.msard.2024.106228
- Citations
- 1
- Primary Topic
- Multiple Sclerosis Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.42
Funders
- Genzyme
- Novartis
- Roche
- Teva Pharmaceutical Industries
- Biogen Idec
- Multiple Sclerosis Society